Advertisement

NLS hemophilia A

Companies - April 15, 2015

Elocta Gets Orphan Status

Swedish Orphan Biovitrum AB has received orphan drug designation in Switzerland for its long acting hemophilia drug candidate Elocta (rFVIIIFc), developed for the treatment of hemophilia A. An orphan drug designation encourages the development of medicines for rare diseases and provides orphan status to drugs and biologics under development.  Elocta is a long-acting recombinant factor […]

Sign up to our Newsletter!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.